© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties
Research Center, Department of Medicine, Department of Pharmacology and Therapeutics, Institut de Cardiologie de Montréal and McGill University, 5000 Bélanger Street East, Montreal, Quebec H1T 1C8, Canada
* Corresponding author. Tel. (+1-514) 376 3330; Fax (+1-514) 376 1355.
Objectives: This study was designed to evaluate how the atrial electrophysiological and antiarrhythmic effects of azimilide compare with those of the specific rapid delayed rectifier (IKr) blocker dofetilide. Background: Azimilide, a new class III drug, was initially believed to be a highly selective blocker of the slow delayed rectifier (IKs), but recent studies suggest that azimilide potently blocks IKr. Thus, it has been suggested that azimilide's in vivo effects may simply be due to IKr blockade. Methods: Dose regimens producing stable effects over time were developed, and two dose levels of azimilide (10 and then 20 mg/kg) or dofetilide (0.08 and then 0.16 mg/kg) were administered to morphine/chloralose-anesthetized dogs during sustained vagal atrial fibrillation (AF). Epicardial mapping was used to measure conduction velocity and AF cycle length. Results: Azimilide terminated AF in 13/14 dogs (93%), while dofetilide terminated AF in 6/12 (50%, P<0.05). While dofetilide had strong reverse use-dependent effects on atrial ERP (e.g. at lower doses, dofetilide increased ERP by 51±3% at a basic cycle length, BCL, of 400 ms and by 17±3% at a BCL of 200 ms), azimilide's effects on ERP were rate-independent (ERP increased at lower dose by 38±6%, BCL 400 ms; 35±10%, BCL 200 ms). Neither drug affected conduction. Conclusions: Azimilide is effective against experimental AF, and increases ERP with a frequency dependence different from the IKr blocker dofetilide, suggesting that azimilide's actions on atrial tissue cannot be attributed exclusively to IKr block, and that effects on other currents (such as IKs) are likely to be important.
KEYWORDS Potassium channel blockers; Cardiac arrhythmias; Antiarrhythmic agents; ECG
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Sticherling, S. Behrens, W. Kamke, A. Stahn, and M. Zabel Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion Europace, January 1, 2005; 7(6): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Singh and N. Wadhani Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S85 - S97. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Nakashima, U. Gerlach, D. Schmidt, and S. Nattel In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions Cardiovasc Res, March 1, 2004; 61(4): 705 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khairy and S. Nattel New insights into the mechanisms and management of atrial fibrillation Can. Med. Assoc. J., October 29, 2002; 167(9): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Derakhchan, C. Villemaire, M. Talajic, and S. Nattel The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF Cardiovasc Res, April 1, 2001; 50(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Verduyn, J. M. v. Opstal, J. D. Leunissen, and M. A. Vos Assessment of the Pro-Arrhythmic Potential of Anti-Arrhythmic Drugs: An Experimental Approach Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 89 - 97. [PDF]
|
|
|
|
|
|
B. D Walker, C. B Singleton, H. Tie, J. A Bursill, K. R Wyse, S. M Valenzuela, S. N Breit, and T. J Campbell Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel Cardiovasc Res, October 1, 2000; 48(1): 44 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Li, A. Benardeau, and S. Nattel Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation Circulation, July 4, 2000; 102(1): 104 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J C Hancox, K C R Patel, and J V Jones Antiarrhythmics---from cell to clinic: past, present, and future Heart, July 1, 2000; 84(1): 14 - 24. [Full Text] [PDF]
|
|
|
|
|
|
P. Dorian and D. Newman Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview Europace, January 1, 2000; 2(4): 277 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Li, L. Zhang, J. Kneller, and S. Nattel Potential Ionic Mechanism for Repolarization Differences Between Canine Right and Left Atrium Circ. Res., June 8, 2001; 88(11): 1168 - 1175. [Abstract] [Full Text] [PDF]
|
|